Literature DB >> 7644772

Bronchial hyperreactivity in patients with endobronchial tuberculosis.

C S Park1, K U Kim, S M Lee, S W Jeong, S Uh, H T Kim, Y H Kim.   

Abstract

Some patients with endobronchial tuberculosis (EBTB) have wheeze on physical examination and normal chest PA, which mimic bronchial asthma. Non-specific bronchial challenge tests have been used to confirm the presence of bronchial hyperreactivity, which is a hallmark of bronchial asthma. To evaluate the effect of endobronchial tuberculous inflammation on bronchial responsiveness to histamine, the provocation concentrations of histamine required to reduce FEV1 by 20% of the pre-challenge baseline (PC20) were compared between patients with EBTB, patients with symptomatic bronchial asthma and normal, healthy controls. PC20 in EBTB patients (17.2 +/- 2.3 mg ml-1) and normal controls (19.5 +/- 1.4 mg ml-1) were significantly higher than in bronchial asthma patients (0.99 +/- 0.15 mg ml-1). PC20 in EBTB patients was not affected by disease location in the bronchial tree was not correlated with FVC or FEV1. In conclusion, one should consider the possibility of EBTB for differential diagnosis from bronchial asthma, if airway responsiveness appears normal in wheezy patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644772     DOI: 10.1016/0954-6111(95)90210-4

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  3 in total

Review 1.  Endobronchial tuberculosis: an overview.

Authors:  Q Xue; N Wang; X Xue; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-16       Impact factor: 3.267

2.  Bronchial anthracosis: a potent clue for diagnosis of pulmonary tuberculosis.

Authors:  Mostafa Ghanei; Jafar Aslani; Mohammadreza Peyman; Masoud Ahmadzad Asl; Omidreza Pirnazar
Journal:  Oman Med J       Date:  2011-01

3.  Investigation of endobronchial tuberculosis diagnoses in 22 cases.

Authors:  X Qingliang; Wang Jianxin
Journal:  Eur J Med Res       Date:  2010       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.